English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Chronic migraine (CM) is a prevalent and disabling neurological disorder. OnabotulinumtoxinA is the only approved therapy specifically for CM. The results from randomized controlled trials often reflect, but rarely define, the spectrum of patient outcomes. The proportion of patients highly responsive to a therapy is an important endpoint and guide for clinicians and patients.

OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT